Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azaserine SCHEMBL20520234 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SLC1A5SMN1; SMN2PNPTP53 | |
| SCHEMBL669596 | 0.79 | CDC7 (0.39) | SMN1; SMN2TP53KDM4ETSHRHSD17B10 | |
| Azaserine SCHEMBL8861 | 0.78 | SLC1A5 (0.38) | SLC1A5SLC7A5IDO1 | |
| Azaserine SCHEMBL8862 | 0.78 | SLC1A5 (0.38) | SLC1A5SLC7A5IDO1 | |
| Azaserine SCHEMBL3312110 | 0.78 | SLC1A5 (0.38) | SLC1A5SLC7A5IDO1 | |
| Azaserine SCHEMBL487222 | 0.78 | SLC1A5 (0.38) | SLC1A5SLC7A5IDO1 | |
| Doxribtimine SCHEMBL3514796 | 0.77 | LMNA (0.48) | TSHR | |
| Azaserine SCHEMBL607082 | 0.77 | SLC1A5 (0.37) | SLC1A5SLC7A5IDO1 | |
| Azaserine SCHEMBL27500218 | 0.77 | SLC1A5 (0.37) | SLC1A5SLC7A5IDO1 | |
| Azathioprine SCHEMBL7757150 | 0.73 | MAPT (0.62) | ALDH1A1SMN1; SMN2TP53KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240094218-A1 | ENHANCED HYBRIDOMA GENERATION | AMGEN INC. (US) | 2024-03-21 | — | — | US | claimed |
| EP-4288450-A1 | ENHANCED HYBRIDOMA GENERATION | Amgen Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
| US-4950598-A | Process for making T cell hybridomas | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1990-08-21 | — | — | US | claimed |
| US-4634666-A | TRIOMAS SECRETING MONOCLONAL ANTIBODIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1987-01-06 | — | — | US | claimed |
| US-20240174758-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| US-20240094218-A1 | ENHANCED HYBRIDOMA GENERATION | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4308607-A2 | THERAPEUTIC BINDING MOLECULE THAT BINDS TO CCR9 | MedImmune Limited (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-4304647-A1 | ANTIBODIES DIRECTED AGAINST GDF-15 | MedImmune, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11845791-B2 | Antibodies directed against GDF-15 | MEDIMMUNE, LLC (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4288450-A1 | ENHANCED HYBRIDOMA GENERATION | Amgen Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-1987005930-A1 | IMMORTALIZED VIRUS-SPECIFIC TISSUE CELLS | GENELABS INCORPORATED (US) | 1987-10-08 | — | — | WO | disclosed |
| EP-0232411-A1 | NON-HUMAN PRIMATE MONOCLONAL ANTIBODIES AND METHODS | GENE LABS, INC. (US) | 1987-08-19 | — | — | EP | disclosed |
| WO-1987001131-A1 | NON-HUMAN PRIMATE MONOCLONAL ANTIBODIES AND METHODS | GENE LABS, INC. (US) | 1987-02-26 | — | — | WO | disclosed |
| US-4634666-A | TRIOMAS SECRETING MONOCLONAL ANTIBODIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1987-01-06 | — | — | US | disclosed |
| US-4624921-A | CULTURES, FUSION | CETUS CORPORATION (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0160550-A2 | Human lymphoblastoid cell line and hybridomas derived therefrom and antibodies produced from such hybridomas, and the production and use of the aforesaid | CETUS CORPORATION (US) | 1985-11-06 | — | — | EP | disclosed |
| EP-0148644-A2 | A novel fusion partner and its products | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1985-07-17 | — | — | EP | disclosed |